Drug Monograph

Drug/Drug Class: **Pradaxa® (dabigatran etexilate mesylate) capsule/ Anticoagulants**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Pradaxa® is now available in a capsule that contains 110 mg of dabigatran etexilate mesylate.
Manufacturer:	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877
Indications:	Pradaxa® is indicated for the reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation, for the treatment of deep venous thrombosis and pulmonary embolism, for the reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism, and for the prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery.
Costs:	$5.83 per capsule of Pradaxa®. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Preferred Agent ☐ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: May 31, 2016

© 2016 Xerox Heritage, LLC All Rights Reserved.